التهاب الأنف التحسسي الخفيف المتقطع: عندما لا تُحل العلاجات الأولية احتقان الأنف أو سيلان الإفرازات أو الأعراض العينية الأنفية

References

• Frequency can be divided into intermittent or persistent (more than four days per week and more than four weeks per year, respectively).
• Severity can be divided into mild (symptoms do not interfere with quality of life) or severe (symptoms impact asthma control, sleep, sports participation, or school or work performance).
• The International Primary Care Respiratory Group; British Society for Allergy and Clinical Immunology; and American Academy of Allergy, Asthma, and Immunology recommend intranasal corticosteroids alone for the initial treatment of persistent symptoms affecting quality of life and second-generation nonsedating antihistamines for mild intermittent disease.
• Consider subcutaneous or sublingual immunotherapy.
• Immunotherapy should be considered for moderate or severe persistent allergic rhinitis that is not responsive to usual treatments, in patients who cannot tolerate standard therapies or who want to avoid long-term medication use, and in patients with allergic asthma.